# Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy

> **NCT01362062** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 110 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT01362062
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-26
- **Primary completion:** 2015-01-01
- **Final completion:** 2015-01-01
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2017-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01362062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01362062, "Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01362062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*